Theophylline and theobromine,their salts and processes for the production thereof



3,459,753 THEOPHYLLINE AND THEOBROMINE, THEIR SALTS AND PROCESSES FOR THE PRODUC- 'IION THEREOF Karl-Heinz Boltze, Bensberg-Kippekausen, and Dietrich Lorenz, Kleinhurden, Germany, assignors to Troponwerke Dinklage 8: Co., a corporation of Germany No Drawing. Filed Nov. 22, 1967, Ser. No. 686,378 Claims priority, application Germany, Nov. 25, 1966,

8 Int. Cl. C07d 57/48, 57/ 42; A61k 27/00 US. Cl. 260-256 1 Claim ABSTRACT OF THE DISCLOSURE Novel theophylline and theobromine compounds and their acid addition salts having analgesic and anti-tussive activity comprising a compound of the formulae:

wherein R represents a radical selected from the group consisting of:

and R represents a member selected from the group consisting of hydrogen, halogen, alkyl, and methoxy.

In accordance with the invention, new theophylline and theobromine compounds, their physiologically acceptable salts and processes for the production of these compounds are claimed. The new compounds exhibit pharmacological properties, more especially analgesic and antitussive action. Therefore, the pharmaceutical preparations produced from these new compounds are also claimed.

Theophylline compounds are employed in many variations in human medicine. The main indication range for these compounds is the heart-circulation field. They improve the coronary circulation, economy of the Work of the heart, peripheral circulation, increase in the blood pressure and the like. In addition, these compounds are employed as central analeptics, to intensify diuresis and to relieve vascular spasms (see Arzneimittelforsching 12, 841 (1962): 13, 470 (1963). Examples of such com pounds are 7-hydroxyethyltheophylline, 7 [l phenyl' propy1-(2)-aminoethyl]theophylline, 7-{[1-phenyl-1 hy droxypropyI-(Z)]-aminoethyl}theophilline and 7-[3 M methyl-N-hydroxyethylamino) 2 hydroxypropyl1theo phylline.

nited States Patent 0 3,459,753 Patented Aug. 5, 1969 The invention relates to new theophylline and theobromine compounds of the general Formula (I) C? CH L/ in which R represents either the theophylline radical or the theobromine radical (a) Reaction of a compound of the general formula R-OHg-CHCH3 or R-CHg-CH-OHgCl o 011 with a compound of the general formula (b) Reaction of theophylline or theobromine or their sodium salts with a compound of the general formula R1 O1OHzCHCH2N N- (c) Reaction of a compound of the general formula in which R represents a halogen atom or a hydroxy group, with a compound of the general formula (d) Reaction of a compound of the general formula ROIIZ?HCH1NHQ with a compound of the general formula Rz-HgC-ILC RZHQCAIEC/ wherein R has the above-indicated meaning.

(e) Reaction of a compound of the general formula RCH2CHCH2-N NH with phenyl lithium or a compound of the general formula (f) Hydrogenation of a compound of the general formula The compound (I) obtained by the above reactions may, if desired, be reacted with a physiologically acceptable acid with the formation of a salt, the radicals R and R in all the foregoing general formulae having the meaning indicated previously.

Of the reactions specified above the embodiment is preferred is the one in which either a compound of the general formula R-CHzCII-CH2 is reacted with a compound of the general formula or a compound of the general formula The ketone compounds mentioned above maybe obtained, for example, by reacting a compound R--CHg-( ]GH2Br with a compound of the general formula L/ In the foregoing general formulae, the radicals R and R have the meanings given above.

In accordance with the invention, it has surprisingly been found that in the compounds produced in accordance with the invention the previously referred to activities of the known theophylline compounds recede substantially or completely into the background in favor of a strong analgesic effect and an antitussive effect. Thus, for example, 7- {3- [4-phenylpiperazinyl- 1 ]-2-hydroxypropyl} theophylline (hereinafter referred to as P) gave in the mouse in the heating plate test an ED of 12.5 mg./kg. (per os) for the analgesic effect, and 1-{-3-[phenylpiperazinyl-(l)]-2-hydroxypropyl}theobromine (hereinafter referred to as Q) an ED of 40 mg./kg., the term ED in this connection being the dose at which no pain reaction is observed in 50% of the experimental animals at a plate temperature of 56 C. within 2 minutes.

In the guinea pig tooth test, P gave an ED of mg./ kg. oral, 6.5 mg./kg. i.v., and Q gave an ED of 70 mg./ kg. oral, 2O mg./kg. i.v.

The ED represents the dose at which an increase of the absolute threshold of at least 50% is observed on 50% of the animals with an electrical stimulus of the dental pulp.

The antitussive effect was tested on the anesthetized cat by electrical stimulation of the N. laiyngicus man. In this case, an ED of less than 5 mg./ kg. enteral and 2 mg./ kg. i.v. was obtained with P, and an ED of 5 mg./kg. enteral and 1 mg./kg. i.v. was obtained with Q, ED in this connection being the dose at which the responsive tussal stimulus to an electrical stimulus is completely suppressed in 50% of the animals.

In addition, in the usual pharmacological tests for both compounds neither a sedative efiect nor a measurable circulary or coronary effect could be observed.

The compounds according to the invention have very low toxicity. The LD of P in the mouse is 630 mg./kg. oral and 220 mg./kg. i.v., and the LD of Q is 710 mg./ kg. oral and 300 mg./kg. iv. (7 days observation period).

The resultant therapeutic index LD /ED which, as is known, is a measure of the safety of the handling of a medicament, is consequently extremely favorable. Chronic toxicity tests carried out on dogs and cats with quantities of 50 to 300 mg./kg./ per diem of active substance (rising) showed neither incompatability nor any side effects.

For the pharmaceutical preparations as an analgesic and antitussive, the active substance is employed in doses of 50 to 400 mg, preferably to 250 mg, per tablet in addition to the usual adjuvants, such as agglutinants. disintegrating agents, flavouring, and the like. In addition to the solid administration forms such as tablets, sugarcoated pills and capsules, which are preferred, liquid forms of administration, for example juices and syrups, are employed.

The following examples illustrate the invention without however limiting it.

Example 1.-1-{ 3- [phenylpiperazinyl- 1 ]-2-hydroxypropyl}theobromine 200 g. of 1-(2,3-epoxypropyl)theobromine and g. of l-phenylpiperazine are dissolved in 200 ml. of benzene and boiled under reflux for 8 hours. The 1-{3-[4-phenylpiperazinyly (1)] 2-hydroxypropyl}theobromine which precipitates on cooling melts at 197-198" C. after recrystallization from benzene.

Yield: 81.5% ,of theory.

Analysis for C H N O Calculated C, 6040%; H 6.59%; N, 21.05%. Found C, 60.12%; H, 6.33%; N 21.10%.

The monohydrochloride prepared with an equivalent quantity of ethanolic hydrochloric acid decomposes from 138 C. with evolution of gas. The dihydrochloride prepared with an excess of ethanolic hydrochloric acid decomposes from 256 C. with evolution of gas.

Analysis for C H N O 2HCl: Calculated C, 51.00%; H, 6.00%; N, 17.85%; C1, 15.00%. Found C, 50.66%; H, 6.15%; N, 17.65%; Cl, 14.72%.

Example 2.1-{3-[4-(3-chlorophenyl)piperazinyl-(1)1- 2-hydroxypropyl}-theobromine.

3.58 g. of 1-(2,3-epoxypropyl) theobromine and 4 g. of 1-(3-chlorophenyl) piperazine dihydrochloride are boiled for 12 hours in absolute alcohol in the presence of twice the equivalent quantity of sodium methoxide. After sodium chloride has been filtered 01f, hydrogen chloride is introduced into this solution and the precipitate is filtered off and washed with ether. The l-{3-[4-(3-chlorophenyl)- piperazinyl-( 1)-]-2-hydroxypropyl}theobromine dihydrochloride monohydrate formed sinters at 215 C. and melts at 230 C.

Analysis for C H CIN O 2HCLH O: Calculated C, 46.00%; H, 5.59%; N, 16.03%; Cl, 20.25%. Found C, 46.46%; H, 5.50%; N, 16.32%; 01, 20.10%.

Example 3.-1-{3- [4- (4-chlorophenyl) piperazinyl-(1)]- 2-hydroxypropyl}-theobrornine 3.5 g. of 1-(2,3-epoxypropyl)theobromine and 4.0 g. of 1-(4-chlorophenyl)piperazine dihydrochloride are boiled for 11.5 hours in 100 ml. of absolute alcohol in the presence of two equivalents of sodium. After working up as described in Example 2, the 1-{3-[4-(4-chlorophenyl)- piperazinyl (1)]-2-hydroxypropyl}theobromine dihydrochloride formed melts at 250 to 255 C.

Analysis for C H CIN O 2HCl: Calculated C, 47.50%; H, 5.39%; N, 16.61%; Cl, 21.05%. Found C, 47.32%; H, 5.64%; N, 16.68%; Cl, 20.60%.

Example 4,-1-{3-[4-(Z-methoxyphenyl)piperazinyl-(1)1- 2-hydroxypropyl}-theobromine 3.5 g. of 1-(2,3-epoxypropyl)theobromine and 3.9 g. of 1-(Z-methoxyphenyl)piperazine dihydrochloride are boiled for 17 hours in absolute alcohol in the presence of 0.64 g. of sodium. The 1-{3-[4-(2-methoxyphenyl)- piperazinyl (1)1-2-hydroxypropyl}theobromine dihydrochloride obtained after working up in the manner described in the foregoing melts at 230 C. with previous sintering.

Analysis for C H N O 2HCl: Calculated C, 50.40%; H, 6.02%; N, 16.78%; Cl, 14.12%. Found C, 50.58%; H, 6.62%; N, 17.28%; Cl, 14.57%.

Examples 5-12 The compounds listed in the following table were prepared by procedures similar to that described in the foregoing examples.

1 After slnterlng at 230 O.

Example 13 .1-{3- [phenylpiperazinyl- 1 ]-2- hydroxypropyl}theobromine 14.5 g. of theobromine and 16.5 g. of 1-(2,3-epoxypropyl)-4-phenylpiperazine are dissolved in about ml. of benzene and boiled under reflux for 6 hours. The crystals precipitating on cooling are recrystallized from benzene. The 1-{3- [4-phenylpiperazinyl- 1 ]-2-hydroxypropyl}theobromine obtained melts at 197198 C. The yield is 23.8 g., corresponding to 78% of theory.

What We claim is:

1. A compound selected from the group consisting of (a) compounds of the formula:

wherein R represents a radical selected from the group consisting of 0 ll l N C Hs l O =\N N 1 CH3 (theophylline) and I CH (theobromine) and R represents a member selected from the group consisting of hydrogen, chlorine and methoxy, and (b) the physiologically acceptable acid addition salts thereof.

References Cited UNITED STATES PATENTS 2,924,598 2/1960 Bestian 260--256 ALEX MAZEL, Primary Examiner ANNE MARIE TIGHE, Assistant Examiner US. Cl. X.'R. 424-253 2 1 3 UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent: No. J Dated August 5, 1909 Inventor) Karl-llelnz Boltze et a1 It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

[- Column 1 lines 25 to 33, the formulel should appear as shown below:

Column 1, lines 37 to 43, the formula should appear-as shown below:

fl- "I! I a;

Column 2, lines 17 to 23, the formula should appear as shown below:

Page 2 mg? UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No. 3,45%753 Dated August 5, 19cm Inventor(s) Karl -Heinz B0 1 tZe et al It is certified that error appears in the above-identified patent and that said Le'rrers Patent are hereby corrected as shown below:

r- Column 4 1 inc 48 "l 3- [pheny] piperazinyl (l -Z-hydroxy should read 1 3 [4 -phenylpiperazinyl (l) j Z-hydroxy- Column #1 line 54 "piperazinyly" should read piperazin Column (1 lines 20 to 33 the formula should appear as she below:

ugcw Column 0, lines 38 to 45 the formula should appear as she below:

l CH3 smmsn lab 'QFM m AUG 2 wmmm E. sum, Edward lamember, Ir. Ohzzmissiom of Fame 

